Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
Stopped early · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy.
Key facts
- Study ID
- NCT00058266
- Run by
- Northwestern University
- People needed
- 36
- Starts
- 2002-12-01
- Expected to finish
- 2009-09-01
- Last updated by the study team
- 2012-07-19
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago — Chicago, Illinois, United States
- Evanston Northwestern Healthcare - Evanston Hospital — Evanston, Illinois, United States
- Ingalls Cancer Care Center at Ingalls Memorial Hospital — Harvey, Illinois, United States
- University of Washington School of Medicine — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.